AAPL VS NVO Stock Comparison

Performance

AAPL
100/100

AAPL returned 13.51% in the last 12 months. Based on SPY's performance of -13.31%, its performance is above average giving it a score of 100 of 100.

NVO
100/100

NVO returned 70.22% in the last 12 months. Based on SPY's performance of -13.73%, its performance is above average giving it a score of 100 of 100.

Analyst Price Targets

AAPL
78/100

38 analysts offer 12-month price targets for AAPL. Together, they have an average target of 190.63, the most optimistic target put AAPL at 240 within 12-months and the most pessimistic has AAPL at 110.

NVO
50/100

1 analysts offer 12-month price targets for NVO. Together, they have an average target of 0, the most optimistic target put NVO at 0 within 12-months and the most pessimistic has NVO at 0.

Sentiment

AAPL
70/100

AAPL had a bullish sentiment score of 70.31% across Twitter and StockTwits over the last 12 months. It had an average of 3,037.82 posts, 116,437.71 comments, and 721,824.29 likes per day.

NVO

"Sentiment" not found for NVO

Technicals

AAPL
18/100

AAPL receives a 17 of 100 based on 14 indicators. 2 are bullish, 11 are bearish.

NVO
50/100

NVO receives a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.

Earnings

AAPL
100/100

AAPL has missed earnings 1 times in the last 20 quarters.

NVO
46/100

NVO has missed earnings 3 times in the last 20 quarters.

Profit

AAPL
76/100

Out of the last 20 quarters, AAPL has had 20 profitable quarters and has increased their profits year over year on 10 of them.

NVO
90/100

Out of the last 20 quarters, NVO has had 20 profitable quarters and has increased their profits year over year on 15 of them.

Volatility

AAPL
45/100

AAPL has had a lower than average amount of volatility over the last 12 months giving it a score of 45 of 100.

NVO
53/100

NVO has had a higher than average amount of volatility over the last 12 months giving it a score of 52 of 100.

Dividend

AAPL
50/100

AAPL's most recent dividend was $0.18 per share, based on a share price of $168.22. It was a payout ratio of 24.99% compared to their total earnings.

NVO

"Dividend" not found for NVO

All score calculations are broken down here to help you make more informed investing decisions

Apple Inc. Summary

Nasdaq / AAPL

Technology

Consumer Electronics

Apple Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide. The company offers iPhone, a line of smartphones; Mac, a line of personal computers; iPad, a line of multi-purpose tablets; and wearables, home, and accessories comprising AirPods, Apple TV, Apple Watch, Beats products, and HomePod. It also provides AppleCare support and cloud services; and operates various platforms, including the App Store that allow customers to discover and download applications and digital content, such as books, music, video, games, and podcasts. In addition, the company offers various services, such as Apple Arcade, a game subscription service; Apple Fitness+, a personalized fitness service; Apple Music, which offers users a curated listening experience with on-demand radio stations; Apple News+, a subscription news and magazine service; Apple TV+, which offers exclusive original content; Apple Card, a co-branded credit card; and Apple Pay, a cashless payment service, as well as licenses its intellectual property. The company serves consumers, and small and mid-sized businesses; and the education, enterprise, and government markets. It distributes third-party applications for its products through the App Store. The company also sells its products through its retail and online stores, and direct sales force; and third-party cellular network carriers, wholesalers, retailers, and resellers. Apple Inc. was incorporated in 1977 and is headquartered in Cupertino, California.

Novo-Nordisk A/S Summary

New York Stock Exchange / NVO

Healthcare

Biotechnology

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Power up your portfolio